Doctor's Notes

Honey for Eczema: Why a Positive Manuka Pilot and a Negative Kanuka Trial Both Matter

Dr. Arsy #003 white moisturizer jar beside an indoor curling arena.

Honey is often discussed as though one promising laboratory result settles whether it helps eczema. The human studies are more complicated. Two small studies used different honeys and different comparison treatments, and they did not produce the same clinical conclusion. Reading both gives a more useful basis for a conversation than choosing the most reassuring headline.

The 2017 manuka pilot was exploratory

The 2017 clinical and mechanistic study evaluated 14 adults with paired eczema lesions over seven nights. It was open-label. Participants used sterilized manuka honey under gauze on one area; the opposite area was left untreated when tolerable. When lesions differed, the slightly more severe area was chosen for honey, rather than randomly allocating the side.

Treated lesions improved on the Three Item Severity score. However, skin staphylococci did not change significantly after seven days. Laboratory effects on cells were separate experiments, not proof of the clinical mechanism. The short, unblinded design, side selection and differing skin coverage limit what can be attributed to honey itself. These findings do not establish long-term flare prevention or treatment of a skin infection.

The 2014 randomized kanuka pilot did not show superiority

A 2014 single-blind randomized study included 15 adults, mean age 37.1 years. It compared medical-grade kanuka honey with aqueous cream on paired areas for two weeks. All participants were analyzed. The between-treatment difference in change in lesion-intensity score was −0.1, 95% CI −1.5 to 1.4; P=0.92. Itch and Three Item Severity changes also did not differ significantly. One participant reported increased itch with honey.

Small size and incomplete masking left uncertainty about smaller effects. The authors also identified aqueous cream as a negative control that was not recommended eczema treatment; its use in this trial is not advice to add it to a routine. The study was sponsored by Honeylab, and an investigator disclosed a relationship with the sponsor.

Study Finding and boundary
Manuka, 2017 Exploratory improvement versus a largely untreated opposite site
Kanuka, 2014 No demonstrated superiority over the study cream control

Different products and controls answer different questions

These trials cannot be combined into a claim that all honey works, or that no honey could ever have an effect. The more practical conclusion is that the evidence is small, formulation-specific and insufficient to support replacing established care. Our guide to interpreting eczema studies explains why comparison treatment and design matter alongside a P value.

A kitchen jar is not the sterilized or medical-grade preparation used in these experiments. Nor does a wound-care use establish eczema efficacy. Before trying an unfamiliar topical product, ask the clinician which ingredients and skin areas are appropriate, how a reaction would be recognized, and what the product is supposed to accomplish.

Keep infection and daily care decisions separate

Do not use honey as a substitute for assessment of painful, spreading or otherwise concerning skin changes. Crusty eczema and antibiotic decisions require their own clinical context. Our skin-microbiome guide also distinguishes detecting bacteria from proving infection or demonstrating treatment benefit.

The AAD's current guideline summary supports established topical approaches, including moisturizers and prescribed anti-inflammatory treatments. Discuss persistent disease with the care team rather than layering several experimental remedies onto the same flare. That makes changes in symptoms easier to interpret and keeps the agreed treatment plan clear.

For another formulation-specific example, see the indigo naturalis vehicle and tacrolimus comparisons. The details of the product and control matter in each case; results cannot be transferred between them.

A separate role for cosmetic moisturizing

Dr. Arsy Moisturizer #003, 4 oz / 120 g is a cosmetic moisturizer for hydration, moisture-barrier support and dry-skin comfort. It does not treat, cure or prevent eczema, replace prescribed care, or inherit results from the study products discussed here. Adult cosmetic testing does not establish infant or pediatric suitability. Read the actual ingredient label and consider individual tolerability.

Educational information, not an individual treatment plan. Sources checked November 9, 2026. The sports image is an AI-created editorial product visual, not a patient photo or a clinical outcome.

← Back to Doctor's Notes